Platelet function and HIV: a case-control study.

Hdl Handle:
http://hdl.handle.net/10147/189931
Title:
Platelet function and HIV: a case-control study.
Authors:
Satchell, Claudette S; Cotter, Aoife G; O'Connor, Eileen F; Peace, Aaron J; Tedesco, Anthony F; Clare, Andrew; Lambert, John S; Sheehan, Gerard J; Kenny, Dermot; Mallon, Patrick W G
Affiliation:
School of Medicine and Medical Sciences, University College Dublin, Ireland. claudette.satchell@ucd.ie
Citation:
Platelet function and HIV: a case-control study. 2010, 24 (5):649-57 AIDS
Journal:
AIDS (London, England)
Issue Date:
13-Mar-2010
URI:
http://hdl.handle.net/10147/189931
DOI:
10.1097/QAD.0b013e328336098c
PubMed ID:
20177361
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed?term=20177361
Abstract:
Cardiovascular disease and myocardial infarction are of increasing concern in HIV-infected populations. Although platelets mediate arterial thrombosis, central to myocardial infarction, data on platelet function in HIV infection are lacking. We hypothesized that HIV-infected patients would have altered platelet reactivity.; A case-control study of platelet reactivity in 20 HIV-infected (HIVpos) and 20 age and sex-matched HIV-negative (HIVneg) individuals.; Time-dependent platelet aggregation was measured in response to increasing concentrations of platelet agonists: epinephrine, collagen, thrombin receptor-activating peptide and ADP using light absorbance.; In both groups, mean age was 34 years, and 65% were men. Sixteen out of 20 (80%) of the HIVpos patients were on antiretroviral therapy with 12 out of 20 (60%) patients having HIV RNA less than 50 copies/ml. There were significant between-group differences in platelet reactivity across all four agonists. Platelets from HIVpos patients were more reactive to epinephrine [mean (SD) log concentration required to induce 50% maximal aggregation, 1.9 (1.2) versus 3.0 (1.7) mumol/l in HIVneg individuals, P = 0.028], whereas less platelet aggregation was observed in response to submaximal concentrations of the other agonists [thrombin receptor-activating peptide 72.5 (14.5)% versus 82.2 (7.6)% at 10 mumol/l, P = 0.011; ADP 67.3 (12.1)% versus 75.2 (8.8)% at 10 mumol/l, P = 0.035; collagen 16.6 (25.1)% versus 35.4 (31.5)% at 71.25 microg/ml, P = 0.007].; Between-group differences in platelet responses to all agonists suggest multiple underlying defects in platelet function in HIV infection. Further research is required to determine the contribution of antiretroviral therapy and relationships between platelet function and the increased cardiovascular disease observed in HIV-infected populations.
Item Type:
Article
Language:
en
Keywords:
HIV INFECTION
MeSH:
Adult; Antiretroviral Therapy, Highly Active; Blood Platelets; Case-Control Studies; Female; HIV Infections; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors
ISSN:
1473-5571

Full metadata record

DC FieldValue Language
dc.contributor.authorSatchell, Claudette Sen
dc.contributor.authorCotter, Aoife Gen
dc.contributor.authorO'Connor, Eileen Fen
dc.contributor.authorPeace, Aaron Jen
dc.contributor.authorTedesco, Anthony Fen
dc.contributor.authorClare, Andrewen
dc.contributor.authorLambert, John Sen
dc.contributor.authorSheehan, Gerard Jen
dc.contributor.authorKenny, Dermoten
dc.contributor.authorMallon, Patrick W Gen
dc.date.accessioned2011-11-18T11:41:14Z-
dc.date.available2011-11-18T11:41:14Z-
dc.date.issued2010-03-13-
dc.identifier.citationPlatelet function and HIV: a case-control study. 2010, 24 (5):649-57 AIDSen
dc.identifier.issn1473-5571-
dc.identifier.pmid20177361-
dc.identifier.doi10.1097/QAD.0b013e328336098c-
dc.identifier.urihttp://hdl.handle.net/10147/189931-
dc.description.abstractCardiovascular disease and myocardial infarction are of increasing concern in HIV-infected populations. Although platelets mediate arterial thrombosis, central to myocardial infarction, data on platelet function in HIV infection are lacking. We hypothesized that HIV-infected patients would have altered platelet reactivity.-
dc.description.abstractA case-control study of platelet reactivity in 20 HIV-infected (HIVpos) and 20 age and sex-matched HIV-negative (HIVneg) individuals.-
dc.description.abstractTime-dependent platelet aggregation was measured in response to increasing concentrations of platelet agonists: epinephrine, collagen, thrombin receptor-activating peptide and ADP using light absorbance.-
dc.description.abstractIn both groups, mean age was 34 years, and 65% were men. Sixteen out of 20 (80%) of the HIVpos patients were on antiretroviral therapy with 12 out of 20 (60%) patients having HIV RNA less than 50 copies/ml. There were significant between-group differences in platelet reactivity across all four agonists. Platelets from HIVpos patients were more reactive to epinephrine [mean (SD) log concentration required to induce 50% maximal aggregation, 1.9 (1.2) versus 3.0 (1.7) mumol/l in HIVneg individuals, P = 0.028], whereas less platelet aggregation was observed in response to submaximal concentrations of the other agonists [thrombin receptor-activating peptide 72.5 (14.5)% versus 82.2 (7.6)% at 10 mumol/l, P = 0.011; ADP 67.3 (12.1)% versus 75.2 (8.8)% at 10 mumol/l, P = 0.035; collagen 16.6 (25.1)% versus 35.4 (31.5)% at 71.25 microg/ml, P = 0.007].-
dc.description.abstractBetween-group differences in platelet responses to all agonists suggest multiple underlying defects in platelet function in HIV infection. Further research is required to determine the contribution of antiretroviral therapy and relationships between platelet function and the increased cardiovascular disease observed in HIV-infected populations.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed?term=20177361en
dc.subjectHIV INFECTIONen
dc.subject.meshAdult-
dc.subject.meshAntiretroviral Therapy, Highly Active-
dc.subject.meshBlood Platelets-
dc.subject.meshCase-Control Studies-
dc.subject.meshFemale-
dc.subject.meshHIV Infections-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMyocardial Infarction-
dc.subject.meshPlatelet Aggregation-
dc.subject.meshPlatelet Aggregation Inhibitors-
dc.subject.meshPlatelet Function Tests-
dc.subject.meshProspective Studies-
dc.subject.meshRisk Factors-
dc.titlePlatelet function and HIV: a case-control study.en
dc.typeArticleen
dc.contributor.departmentSchool of Medicine and Medical Sciences, University College Dublin, Ireland. claudette.satchell@ucd.ieen
dc.identifier.journalAIDS (London, England)en
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.